These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy? Müller ML; Butler J; Heidecker B Eur J Heart Fail; 2020 Jan; 22(1):39-53. PubMed ID: 31912620 [TBL] [Abstract][Full Text] [Related]
32. Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy. Park J; Egolum U; Parker S; Andrews E; Ombengi D; Ling H Ann Pharmacother; 2020 May; 54(5):470-477. PubMed ID: 31735059 [No Abstract] [Full Text] [Related]
33. Review of Transthyretin Silencers, Stabilizers, and Fibril Removal Agents in the Treatment of Transthyretin Cardiac Amyloid. Hough A; Wearden J; de Almeida K; Kaiser S Curr Cardiol Rep; 2020 Aug; 22(10):106. PubMed ID: 32770401 [TBL] [Abstract][Full Text] [Related]
35. Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience. Siddiqi OK; Mints YY; Berk JL; Connors L; Doros G; Gopal DM; Kataria S; Lohrmann G; Pipilas AR; Ruberg FL Amyloid; 2022 Jun; 29(2):71-78. PubMed ID: 35083944 [TBL] [Abstract][Full Text] [Related]
36. Amyloid Cardiomyopathy in the Rare Transthyretin Tyr78Phe Mutation. Tini G; Vianello PF; Gemelli C; Grandis M; Canepa M J Cardiovasc Transl Res; 2019 Dec; 12(6):514-516. PubMed ID: 30604309 [TBL] [Abstract][Full Text] [Related]
37. Estimating the health benefits of timely diagnosis and treatment of transthyretin amyloid cardiomyopathy. Rozenbaum MH; Large S; Bhambri R; Stewart M; Young R; Doornewaard AV; Dasgupta N; Masri A; Nativi-Nicolau J J Comp Eff Res; 2021 Aug; 10(11):927-938. PubMed ID: 34142865 [No Abstract] [Full Text] [Related]
38. Screening for Transthyretin Amyloid Cardiomyopathy in Everyday Practice. Witteles RM; Bokhari S; Damy T; Elliott PM; Falk RH; Fine NM; Gospodinova M; Obici L; Rapezzi C; Garcia-Pavia P JACC Heart Fail; 2019 Aug; 7(8):709-716. PubMed ID: 31302046 [TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of systematic screening and treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) in patients with heart failure with preserved ejection fraction (HFpEF) in United States. Lau ATC; DiDomenico RJ; Kim K Int J Cardiol; 2024 Mar; 398():131598. PubMed ID: 37979789 [TBL] [Abstract][Full Text] [Related]